CHEK2 and breast carcinoma: Where our analysis is restricted to low-TIL BRCAX and CHEK2*1100delC mutated breast cancers of the luminal subtypes, Nagel et al. performed their analysis on all hormone receptor positive breast cancers, including high-TIL and BRCA1/BRCA2 mutated samples.